Skip to main content

Table 1 Characteristics of patients, primary tumours, oligometastatic tumours and SBRT characteristics

From: Analyses of the local control of pulmonary Oligometastases after stereotactic body radiotherapy and the impact of local control on survival

Characteristic Distribution Number (%)
All tumours   1547
Sex Male 994 (64.3)
  Female 553 (35.7)
Age, years Median, range, IQR 72; 16–93; 63–78
ECOG Performance Status 0 841 (54.4)
  1 529 (34.2)
  2 90 (5.8)
  3 19 (1.2)
  Missing 68 (4.4)
Primary lesion sites Lung 451 (29.2)
  Colorectum 391 (25.3)
  Head and Neck 126 (8.1)
  Oesophagus 132 (8.5)
  Others 447 (28.9)
Pathology of primary lesion Adenocarcinoma 861 (55.7)
  Squamous cell carcinoma 396 (25.6)
  Sarcoma 47 (3.0)
  Others 168 (10.9)
  Missing 75 (4.8)
Control method of primary lesion Surgery 1222 (79.0)
  Chemoradiation 130 (8.4)
  Radiation (X-ray or particle) 70 (4.5)
  Others 40 (2.6)
  Missing 85 (5.5)
Disease-free interval, months Median, range, IQR 17.5; 0–423.9; 8.0–34.3
Oligometastatic state Oligo-recurrences 1157 (74.8)
  Sync-oligometastases 133 (8.6)
  Unclassified 133 (8.6)
  Missing 124 (8.0)
SBRT performed institution Academic 642 (41.5)
  Non-academic 905 (58.5)
Date SBRT was performed 2004–2009 518 (33.5)
  2010–2015 1029 (66.5)
Chemotherapy Before SBRT Yes, 591 (38.2)
No, 945 (61.1)
Missing, 11 (0.7)
  Concurrent with SBRT Yes, 34 (2.2)
No, 1513 (97.8)
  After SBRT Yes, 242 (15.6)
No, 998 (64.5)
Missing, 307 (19.9)
Maximum tumour diameter, cm Median, range, IQR 1.5; 0.3–6.5; 1.0–2.0
Number of oligometastases at the time of emergence of the SBRT-targeted tumour 1 1036 (67.0)
2–5 503 (32.5)
Missing 8 (0.5)
Lung lobe involved with treated tumour Right upper lobe 293 (18.9)
Right middle lobe 83 (5.4)
  Right lower lobe 321 (20.8)
  Left upper lobe 294 (19.0)
  Left lower lobe 226 (14.6)
  Unknown lobe Right lung, 12; Left lung, 7
  Missing 311 (20.1)
Beams Multiple static 1145 (74.0)
  Arc 401 (25.9)
  Missing 1 (0.1)
X-ray energy 4 MV only 202 (13.1)
  6 MV only 1179 (76.2)
  Others 160 (10.3)
  Missing 6 (0.4)
Field coplanarity Coplanar field 1139 (73.6)
  Non-coplanar field 404 (26.1)
  Missing 4 (0.3)
Dose calculation algorithm Type A 541 (35.0)
  Type B 799 (51.6)
  Type C 144 (9.3)
  Missing 63 (4.1)
Dose prescription IC 1103 (71.3)
  D95 of PTV 317 (20.5)
  Others 127 (8.2)
BED10 at isocenter, Gy Median, range, IQR 105.6; 75.0–289.5; 105.6–126.9
Number of SBRT fractions 2–3 27 (1.7)
  4 959 (62.0)
  5 236 (15.3)
  6–16 324 (20.9)
  missing 1 (0.1)
OTT of SBRT, day Median, range, IQR 7; 3–81; 4–11
  1. Abbreviations: SBRT Stereotactic body radiotherapy, IQR Interquartile range, ECOG Eastern Cooperative Oncology Group, IC Isocenter, D95 of PTV Dose covering 95% of planning target volume, BED Biological effective dose, OTT Overall treatment time